Premium
Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: A case series
Author(s) -
KU Geoffrey Y,
DE LIMA LOPES Jr Gilberto,
CHANG Alex Y
Publication year - 2011
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2010.01345.x
Subject(s) - bevacizumab , oxaliplatin , medicine , doxorubicin , sorafenib , cirrhosis , hepatocellular cancer , hepatocellular carcinoma , liver cancer , oncology , chemotherapy , gastroenterology , cancer , colorectal cancer
Aims: Despite the emergence of sorafenib as the standard treatment for patients with advanced hepatocellular cancer (HCC), therapy remains sub‐optimal and toxic. Methods: We report on five patients with advanced HCC treated with bevacizumab, oxaliplatin and doxorubicin or liposomal doxorubicin. Results: Of the five patients, four had cirrhosis; two patients had Child‐Pugh A cirrhosis, while one each had Child‐Pugh B and C cirrhosis. Grade 3/4 toxicity was uncommon. Four patients had a decrease of ≥50% in alpha‐fetoprotein levels following therapy and one patient each had a radiographic complete response and stable disease. Conclusion: These data add to the growing phase II data that bevacizumab‐containing regimens are active in advanced HCC patients. Further evaluation of regimens containing bevacizumab with oxaliplatin and/or doxorubicin may be warranted.